Comparison of bortezomib with dexamethasone and thalidomide with dexamethasone in the treatment of patients with monoclonal immunoglobulin deposition disease.
Bortezomib/dexamethasone followed by autologous stem cell transplantation is recommended for transplant-eligible patients, while bortezomib/dexamethasone alone remains effective for those who are ineligible, which supports bortezomib/dexamethasone as first-line therapy.